National Cancer Institute; Notice of Meeting, 26772 [2012-10964]
Download as PDF
<![CDATA[
26772
Federal Register / Vol. 77, No. 88 / Monday, May 7, 2012 / Notices
sroberts on DSK5SPTVN1PROD with NOTICES
Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 3130,
MSC 7850, Bethesda, MD 20892, 301–435–
3009, elliotro@csr.nih.gov.
Name of Committee: Center for Scientific
Review Special Emphasis Panel; PAR Panel:
FIRCA and GRIP Review.
Date: May 31–June 1, 2012.
Time: 8:00 a.m. to 5:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: Hotel Monaco Washington DC, 700
F Street NW., Washington, DC 20004.
Contact Person: Hilary D Sigmon, Ph.D.,
Scientific Review Officer, Center for
Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 5222,
MSC 7852, Bethesda, MD 20892, (301) 594–
6377, sigmonh@csr.nih.gov.
Name of Committee: Center for Scientific
Review Special Emphasis Panel; Member
Conflict: Obesity-Clinical Research.
Date: June 1, 2012.
Time: 10:00 a.m. to 3:30 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health, 6701
Rockledge Drive, Bethesda, MD 20892,
(Virtual Meeting).
Contact Person: Krish Krishnan, Ph.D.,
Scientific Review Officer, Center for
Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 6164,
MSC 7892, Bethesda, MD 20892, (301) 435–
1041, krishnak@csr.nih.gov.
Name of Committee: Healthcare Delivery
and Methodologies Integrated Review Group;
Societal and Ethical Issues in Research Study
Section.
Date: June 4, 2012.
Time: 8:00 a.m. to 5:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: Hyatt Regency Bethesda, One
Bethesda Metro Center, 7400 Wisconsin
Avenue, Bethesda, MD 20814.
Contact Person: Karin F Helmers, Ph.D.,
Scientific Review Officer, Center for
Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 3166,
MSC 7770, Bethesda, MD 20892, 301–254–
9975, helmersk@csr.nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.306, Comparative Medicine;
93.333, Clinical Research, 93.306, 93.333,
93.337, 93.393–93.396, 93.837–93.844,
93.846–93.878, 93.892, 93.893, National
Institutes of Health, HHS)
Dated: May 1, 2012.
Jennifer S. Spaeth,
Director, Office of Federal Advisory
Committee Policy.
[FR Doc. 2012–10969 Filed 5–4–12; 8:45 am]
BILLING CODE 4140–01–P
VerDate Mar<15>2010
18:11 May 04, 2012
Jkt 226001
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Cancer Institute; Notice of
Meeting
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended (5 U.S.C. App.), notice is
hereby given of the meeting of the NCIFrederick Advisory Committee.
The meeting will be open to the
public as indicated below, with
attendance limited to space available.
Individuals who plan to attend and
need special assistance, such as sign
language interpretation or other
reasonable accommodations, should
notify the Contact Person listed below
in advance of the meeting.
A portion of the meeting will be
closed to the public in accordance with
the provisions set forth in section
552b(c)(9)(B), Title 5 U.S.C., as
amended. The premature disclosure of
information to be discussed during the
meeting would significantly frustrate
implementation of a proposed agency
action.
Name of Committee: NCI-Frederick
Advisory Committee.
Open: May 30, 2012, 9:00 a.m. to 11:00
a.m.
Agenda: Ongoing and New Business and
Scientific Presentations.
Place: National Institutes of Health, 9000
Rockville Pike, Building 31, C Wing, 6th
Floor, Conference Room 10, Bethesda, MD
20892.
Closed: May 30, 2012, 11:00 a.m. to 3:00
p.m.
Agenda: Discussion of Proposed Frederick
National Laboratory Strategic Plan.
Place: National Institutes of Health, 9000
Rockville Pike, Building 31, C Wing, 6th
Floor, Conference Room 10, Bethesda, MD
20892.
Contact Person: Thomas M. Vollberg, Sr.,
Ph.D., Executive Secretary, National Cancer
Institute, National Institutes of Health, 6116
Executive Boulevard, 7th Floor, Room 7142,
Bethesda, MD 20892–8327, (301) 694–9582.
Any interested person may file written
comments with the committee by forwarding
the statement to the Contact Person listed on
this notice. The statement should include the
name, address, telephone number and when
applicable, the business or professional
affiliation of the interested person.
In the interest of security, NIH has
instituted stringent procedures for entrance
onto the NIH campus. All visitor vehicles,
including taxicabs, hotel, and airport shuttles
will be inspected before being allowed on
campus. Visitors will be asked to show one
form of identification (for example, a
government-issued photo ID, driver’s license,
or passport) and to state the purpose of their
visit.
Information is also available on the
Institute’s/Center’s home page: https://
PO 00000
Frm 00048
Fmt 4703
Sfmt 4703
deainfo.nci.nih.gov/advisory/fac/fac.htm,
where an agenda and any additional
information for the meeting will be posted
when available.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.392, Cancer Construction;
93.393, Cancer Cause and Prevention
Research; 93.394, Cancer Detection and
Diagnosis Research; 93.395, Cancer
Treatment Research; 93.396, Cancer Biology
Research; 93.397, Cancer Centers Support;
93.398, Cancer Research Manpower; 93.399,
Cancer Control, National Institutes of Health,
HHS)
Dated: April 27, 2012.
Jennifer S. Spaeth,
Director, Office of Federal Advisory
Committee Policy.
[FR Doc. 2012–10964 Filed 5–4–12; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
Prospective Grant of Exclusive
License: Ocular Therapeutics Agent
Delivery Devices and Methods for
Making and Using Such Devices
National Institutes of Health,
Public Health Service, HHS.
ACTION: Notice.
AGENCY:
This is notice, in accordance
with 35 U.S.C. 209(c)(1) and 37 CFR
404.7(a)(1)(i), that the National
Institutes of Health (NIH), Department
of Health and Human Services, is
contemplating the grant of an exclusive
patent license to practice the inventions
embodied in Patent Applications USSN
09/808,149, filed Mar 15, 2001, issued
Mar 30, 2004; PCT/US02/07836, filed
Mar 14, 2002, designated EP,
02723446,7 and US 10/471,468, issued
Feb 9, 2010; USSN 11/739,540, filed
Apr 29, 2007; and USSN 12/647,980,
filed Dec 28, 2009; entitled ‘‘Ocular
Therapeutic Agent Delivery Devices and
Methods For Making and Using Such
Devices’’, by Michael R. Robinson et al
(NEI, CC, and NIBIB) (E–241–1999/0), to
ODIN Biotech having a place of business
in 4000 Hanover Street, Dallas, TX. The
patent rights in this invention have been
assigned to the United States of
America. The exclusive patent license is
one which qualifies under the Start-up
Exclusive Patent License Agreement
program, which is in place from October
1, 2011 through September 30, 2012.
DATES: Only written comments and/or
application for a license that are
received by the NIH Office of
Technology Transfer on or before May
22, 2012 will be considered.
SUMMARY:
E:\FR\FM\07MYN1.SGM
07MYN1
]]>Agencies
[Federal Register Volume 77, Number 88 (Monday, May 7, 2012)]
[Notices]
[Page 26772]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 2012-10964]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
National Cancer Institute; Notice of Meeting
Pursuant to section 10(d) of the Federal Advisory Committee Act, as
amended (5 U.S.C. App.), notice is hereby given of the meeting of the
NCI-Frederick Advisory Committee.
The meeting will be open to the public as indicated below, with
attendance limited to space available. Individuals who plan to attend
and need special assistance, such as sign language interpretation or
other reasonable accommodations, should notify the Contact Person
listed below in advance of the meeting.
A portion of the meeting will be closed to the public in accordance
with the provisions set forth in section 552b(c)(9)(B), Title 5 U.S.C.,
as amended. The premature disclosure of information to be discussed
during the meeting would significantly frustrate implementation of a
proposed agency action.
Name of Committee: NCI-Frederick Advisory Committee.
Open: May 30, 2012, 9:00 a.m. to 11:00 a.m.
Agenda: Ongoing and New Business and Scientific Presentations.
Place: National Institutes of Health, 9000 Rockville Pike,
Building 31, C Wing, 6th Floor, Conference Room 10, Bethesda, MD
20892.
Closed: May 30, 2012, 11:00 a.m. to 3:00 p.m.
Agenda: Discussion of Proposed Frederick National Laboratory
Strategic Plan.
Place: National Institutes of Health, 9000 Rockville Pike,
Building 31, C Wing, 6th Floor, Conference Room 10, Bethesda, MD
20892.
Contact Person: Thomas M. Vollberg, Sr., Ph.D., Executive
Secretary, National Cancer Institute, National Institutes of Health,
6116 Executive Boulevard, 7th Floor, Room 7142, Bethesda, MD 20892-
8327, (301) 694-9582.
Any interested person may file written comments with the
committee by forwarding the statement to the Contact Person listed
on this notice. The statement should include the name, address,
telephone number and when applicable, the business or professional
affiliation of the interested person.
In the interest of security, NIH has instituted stringent
procedures for entrance onto the NIH campus. All visitor vehicles,
including taxicabs, hotel, and airport shuttles will be inspected
before being allowed on campus. Visitors will be asked to show one
form of identification (for example, a government-issued photo ID,
driver's license, or passport) and to state the purpose of their
visit.
Information is also available on the Institute's/Center's home
page: https://deainfo.nci.nih.gov/advisory/fac/fac.htm, where an
agenda and any additional information for the meeting will be posted
when available.
(Catalogue of Federal Domestic Assistance Program Nos. 93.392,
Cancer Construction; 93.393, Cancer Cause and Prevention Research;
93.394, Cancer Detection and Diagnosis Research; 93.395, Cancer
Treatment Research; 93.396, Cancer Biology Research; 93.397, Cancer
Centers Support; 93.398, Cancer Research Manpower; 93.399, Cancer
Control, National Institutes of Health, HHS)
Dated: April 27, 2012.
Jennifer S. Spaeth,
Director, Office of Federal Advisory Committee Policy.
[FR Doc. 2012-10964 Filed 5-4-12; 8:45 am]
BILLING CODE 4140-01-P
